A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers (NCT04372719) | Clinical Trial Compass
CompletedPhase 1
A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers
36 participantsStarted 2016-11-02
Plain-language summary
This is a non-controlled, open-label, single-centre, dose-escalation study to determine the safety, infectivity and immunology of the potential novel influenza virus H3N2 challenge strain. The term 'challenge agent' used in this protocol refers to the Influenza virus H3N2 A/Belgium/4217/2015. The study utilises an adaptive study design and consists of 2 parts.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female, between 18 and 55 years old (extremes included) at screening.
✓. In good physical and mental health as determined on the basis of medical history and general physical examination performed at screening.
✓. Absent or low levels of detectable pre-existing antibodies to influenza virus subtypes, including as a minimum the challenge strain, as determined by a MNT titre of ≤ 20 at screening.
✓. Negative urine test for selected drugs of abuse at screening and upon check-in at the clinical site.
✓. Negative alcohol breath test
✓. Female subjects should fulfil one of the following criteria:
✓. At least 1 year post-menopausal (amenorrhea \>12 months and/or follicle-stimulating hormone (FSH) \> 30 mIU/mL) prior to screening;
✓. Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation);
Exclusion criteria
✕. Subjects who have received any vaccination within the last 3 months prior to screening or influenza vaccine within the last 12 months prior to screening or who anticipate receiving this during the study.
✕. Subjects with a diagnosis of influenza or influenza-like illness confirmed by a physician within the last 6 months prior to screening.
✕. Subjects with a positive result for adventitious agent screening (qualitative PCR testing) for any respiratory virus or bacteria on Day -2.
What they're measuring
1
safety profile
Timeframe: through study completion, an average of 3 months
2
Efficacy: Infectivity
Timeframe: through study completion, an average of 3 months
3
Efficacy: observed attack rate
Timeframe: through study completion, an average of 3 months
Trial details
NCT IDNCT04372719
SponsorSGS Life Sciences, a division of SGS Belgium NV
✕. Haematology and chemistry parameters, pulse rate and/or blood pressure, and ECG outside the reference range for the population studied and considered as clinical significant by the Investigator.